medscape.com
Cure8 news brief
Why This Matters
The study suggests rituximab — an anti-CD20 therapy commonly used off-label for MS in some countries — may increase the chance of developing IBD compared with other MS treatments. Even though the absolute number of new IBD cases was small, the relative increase could affect treatment discussions and monitoring.
Who Should Pay Attention
People with relapsing-remitting MS considering or receiving rituximab or other DMTs, neurologists, gastroenterologists, and clinicians who monitor MS patients for new gastrointestinal symptoms.
Study Snapshot
Story typeResearch news
Evidence typeObservational study
Source depthFull source text
What To Know
The study compared rituximab-treated RRMS patients to those receiving natalizumab, dimethyl fumarate, or fingolimod and to matched people without MS using national health registers.
After adjustment for demographic and MS-related factors, rituximab was associated with about a 10-fold higher hazard of new IBD compared with the grouped other-DMT comparator, with a median time to diagnosis of roughly 3 years.
The authors note limitations including small numbers of IBD cases in some comparison groups, potential residual confounding, and reliance on diagnostic codes. Clinicians and patients should weigh this potential risk against rituximab’s benefits for controlling MS inflammation and monitor for new gastrointestinal symptoms during treatment.
Keep In Mind
The findings come from a Swedish registry-based observational study with potential residual confounding and diagnostic-code–based outcome ascertainment; rituximab use and IBD rates may differ by country and clinical practice. The absolute cumulative incidence of IBD remained under 2% at 10 years.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedscape.com
AuthorsLizette Borreli
Indexed viaGoogle News
Source typeWeb article
PublishedNov 3, 2026, 11:58 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Methotrexate for IBD: How Do GIs Use It? - Medscape
Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...
Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study.
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...